Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report-Reference-Cited by-同舟云学术

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report

Published:2021-06-09 Issue:14 Volume:12 Page:2130-2133
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Bing Zhongxing¹,Jia Ziqi¹²,Wang Yadong¹²,Xue Jianchao¹³,Cao Lei¹,Cao Zhili¹,Liu Peng⁴,Li Ji⁵,Liang Naixin¹^ORCID,Li Shanqing¹

Affiliation:

1. Department of Thoracic Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China

2. Peking Union Medical College Eight‐Year MD Program, Chinese Academy of Medical Sciences Beijing China

3. Peking Union Medical College Chinese Academy of Medical Sciences Beijing China

4. Medical Research Center, Central Laboratory Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China

5. Department of Pathology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14045

Reference8 articles.

1. Ceritinib inALK-Rearranged Non–Small-Cell Lung Cancer

2. Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement

3. Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer

4. Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report

5. Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report;Heliyon;2023-11

2. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report;American Journal of Case Reports;2023-10-30

3. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer;Targeted Oncology;2023-06-23

4. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports;Frontiers in Oncology;2023-06-20

5. Challenges of neoadjuvant targeted therapy in early stage non-small cell lung cancer—a narrative review;AME Surgical Journal;2023-04